尽管减肥、糖尿病药物销售不佳,拖累礼来Q4营收略不及预期,但公司每股收益仍超华尔街预期。 美东时间2月6日周四美股盘前,制药巨头礼来公布2024财年第四季度业绩,及2025财年业绩指引。 1)主要财务数据 营收:Q4营收135.3亿美元,同比增长45%,略低于预期的135.7亿美元。 净利润:Q4净利润44.1亿美元,同比增长101%。 EPS:Q4调整后每股收益为5.32美元,高于预期的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.